Back to results
US 2017/0246200 A1Published application
Microrna-132/212 for the treatment of neurodegenerative disorders
AssigneeUniversite Laval
InventorSébastien HEBERT
Life of this patent
Estimating the term…
Abstract
The present relates to the use of miRNA-132/212 mimics or activators comprising a doubled stranded ribonucleic acid molecule comprising a seed region sequence of miRNA-132 or miRNA-212, a spacer, a stabilizing sequence, and a carrier for the treatment of neurodegenerative disorders, including Alzheimer's disease, Tauopathies, Amyotrophic lateral sclerosis, Parkinson's disease, frontotemporal dementia, prion's disease, mild cognitive impairment and Huntington's disease.
Claims26
A pharmaceutical composition comprising:
- a doubled stranded ribonucleic acid molecule comprising a seed region sequence of miRNA-132 or miRNA-212, a spacer, and a stabilizing sequence;
- and
- a carrier.
10-15. (canceled)
(canceled)
20-24 (cancelled)
30-34. (canceled)
36-37. (canceled)
40-44. (canceled)
Dependencies are inferred from the claim text.